Effects of some novel inhibitors of C17,20-lyase and 5α-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer

Cancer Research

Volumn 58, Issue 17, 1998, Pages 3826-3832

  Nnane, Ivo P ^a   Kato, Katsuya ^a,b   Liu, Yang ^a   Lu, Qing ^a   Wang, Xin ^a   Ling, Yang Zhi ^a,c   Brodie, Angela ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

Author keywords

[No Author keywords available]

Indexed keywords

17 (3' PYRAZOLYL)ANDROSTA 4,16 DIEN 3BETA ONE; 17 (3' PYRAZOLYL)ANDROSTA 5,16 DIEN 3BETA OL; 17BETA (4' IMIDAZOLYL)ANDROST 4 EN 3 ONE; 20 HYDROXIMINO 4,16 PREGNADIEN 3 ONE; ANTINEOPLASTIC AGENT; ENZYME INHIBITOR; FINASTERIDE; KETOCONAZOLE; STEROID 17,20 LYASE; STEROID 5ALPHA REDUCTASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CANCER CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENCY; DRUG STRUCTURE; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; MALE; MALE GENITAL TRACT CANCER; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT; SUBCUTANEOUS DRUG ADMINISTRATION; TESTOSTERONE BLOOD LEVEL;

ANDROGENS; ANIMALS; CHOLESTENONE 5 ALPHA-REDUCTASE; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; FINASTERIDE; HUMANS; KETOCONAZOLE; MALE; ORGAN SIZE; OXIDOREDUCTASES; PROSTATE; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; STEROID 17-ALPHA-HYDROXYLASE; TESTOSTERONE;

EID: 0032170937     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Dijkman, G. A., and Debruyne, F. M. Epidemiology of prostate cancer. Eur. Urol., 30: 281-295, 1996.
2. Whittemore, A. S. Prostate Cancer. In: R. Doll, J. F. Fraumeni, and C. S. Muir (eds.), Cancer Surveys: Trends in Cancer Incidence and Mortality, Vol. 19/20, pp. 309-322. Cold Spring Harbor, NY; Cold Spring Harbor Laboratory, 1994.
3. Cheng, E., Lee, C., and Grayhack, J. Endocrinology of the prostate. In: H. Lepor and R. K. Lawson (eds.), Prostate Diseases, pp. 57-71. Philadelphia: W. B. Saunders, 1993.
4. 21 steroid side chain cleavage: spectral and binding studies. J. Biol. Chem., 256: 6134-6139, 1981.
5. Bruchovsky, N., and Wilson J. D. The conversion of testosterone to 5α-androsta-17α-ol-3-one by rat prostate in vivo and in vitro. J. Biol. Chem., 243: 2012-2021, 1968.
6. Saunders F. J. Some aspects of relation of structure of steroids to their prostate stimulating effects. In: E. P. Vollmer (ed.), Prostate and Related Tissues, National Cancer Institute Monograph No. 12, pp. 139-159. Washington, DC: United States Government Printing Office, 1963.
7. Wilson, J. D. Role of dihydrotestosterone in androgen action. Prostate Suppl., 6: 88-92, 1996.
8. Peterson, R. E., Imperanto-McGinley, J., Gautier T., and Sturla, E. Male pseudohemaphroditism due to steroid 5-α-reductase deficiency. Am. J. Med., 62: 170-191, 1977.
9. Meikle, A. W., Smith, J. A., and Stringham J. D. Production, clearance and metabolism of testosterone in men with prostatic cancer. Prostate, 10: 25-31, 1987.
10. Labrie, F., Dupont, A., Belanger, A., Lacoursiere, Y., Raynaud, J. P., Husson, J. M., Gareau, J., Fazekas, A. T. A., Sandow, J., Monfette, G., Girard, J. G., Emond, J., and Houle, J. G. New approach in the treatment of prostate cancer: complete instead of partial withdrawal of androgens. Prostate, 4: 579-594, 1983.
11. Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davies, M. A., and Goodman, P. J. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N. Engl. J. Med., 321: 419-424, 1989.
12. 17,20lyase). Biochem. Biophys. Res. Commun., 162: 1571-1577, 1989.
13. Ayub, M., and Levell, M. J. Inhibition of testicular 17α-hydroxylase and 17,20-lyase but not 3-hydroxysteroid dehydrogenase-isomerase or 17-hydroxysteroid oxidoreductase by ketoconazole and other imidazole drugs. J. Steroid Biochem., 28: 521-531, 1987.
14. 17,20lyase). Chem. Pharm. Bull. (Tokyo), 7: 1855-1858, 1989.
15. 21-steroids. Yakugaku Zasshi, 108: 1188-1195, 1988.
16. Jarman, M., Barrie, S. E., Deadman, J. J., Houghton, J., and McCague, R. Novel inhibitors of enzymes of androgen biosynthesis. J. Med. Chem., 33: 3050-3055, 1990.
17. McCague, R., Rowlands, M. G., Barrie, S. E., and Houghton, J. Inhibition of enzymes of estrogen and androgen biosynthesis by ester of 4-pyridylacetic acid. J. Med. Chem., 33: 3050-3055, 1990.
18. Trachtenberg, J. Ketoconazole therapy in advanced prostatic cancer. J. Urol., 132: 61-63, 1984.
19. Williams, G., Kerle, D. J., Doble, A., Dunlop, H., Smith, C., Allen, J., Yeo, T., and Bloom, S. R. Objective responses to ketoconazole therapy in patients with relapsed progressive prostatic cancer. Br. J. Urol., 58: 45-51, 1986.
20. Stoner, E. The clinical development of 5α-reductase inhibitor, finasteride. J. Steroid Biochem. Mol. Biol., 37: 375-378, 1990.
21. Cohen, S. M., Werrman, G. H., Rasmussen, G. H., Tankaka, W. K., Malatesta, P. F., Prahalada, J. G., Jacobs, J. G., Harris, G., and Nett, T. M. Comparison of the effects of new azasteroids inhibitors of steroid 5α-reductase on canine hyperplastic prostate: suppression of prostatic DHT correlated with prostate regression. Prostate, 26: 55-71, 1995.
22. Geller, J. Effects of finasteride, a 5α-reductase inhibitor of prostate tissue androgens and prostate specific antigen. J. Clin. Endocrinol. Metab., 71: 1552-1555, 1990.
23. Gormley, G. J. Role of 5α-reductase inhibitors in the treatment of advanced prostatic carcinoma. Urol. Clin. North Am. 18: 93-97, 1991.
24. Li, J., Li, Y. Son, C., and Brodie, A. M. H. Inhibition of androgen synthesis by 22-hydroximino-23,24-bisnor-4-cholen-3-one. Prostate, 26: 140-150, 1995.
25. Klus, G. T., Nakamura, J., Li, J. Ling, Y. Son, C., Kemppainen, J. A., Wilson, E. M., and Brodie, A. M. H. Growth inhibition of human prostate cells in vitro by novel inhibitors of androgen synthesis. Cancer Res., 56: 4956-4964, 1996.
26. 17,20lyase and of 5α-reductase. J. Steroid Biochem. Mol. Biol., 42: 313-321, 1992.
27. 17αa) J. Med. Chem., 40: 3297-3304, 1997.
28. 17,20lyase. J. Med. Chem., 39: 4335-4339, 1996.
29. 17αa): potent inhibitors for the treatment of prostate cancer. J. Med. Chem., 41: 902-912, 1998.
30. Lowry, O. H., Roseborough, N. S., Farr, A. L., and Randall, R. S. Protein measurement with the folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
31. Gormley, G. J., Stoner, E., Bruskewitz, R. C., Imperanto-McGinley, J., Walsh, P. C., McConnel, J. D., Andriole, G. L., Geller, J., Brachen, B. R., Tenover, J. S., Vaughan, E. D., Pappas, F., Taylor, A., Binkowitz, B., and Ng, J. The effects of finasteride in men with prostatic hyperplasia. N. Engl. J. Med., 327: 1185-1191, 1992.
32. Peters, D. H., and Sorkin, M. Finasteride: a review of its potential in the treatment of benign prostatic hyperplasia. Drugs, 46: 177-208, 1993.
33. Homma, Y., Kaneko, M., Kondo, Y., Kawabe, K., and Kakizoe, T. Inhibition of rat prostate carcinogenesis by a 5α-reductase inhibitor, FK143. J. Natl. Cancer Inst. (Bethesda), 89: 803-807, 1997.
34. Kadohama, N., Karr, J. P., Murphy, G. P., and Sandberg, A. A. Selective inhibition of prostatic tumour 5α-reductase by a 4-methyl-4-azasteroid. Cancer Res., 44: 4947-4954, 1984.
35. Lamb, J. C., Levy, M. A., Johnson, R. K., and Isaacs, J. T. Response to rat and human prostate cancer to the novel 5α-reductase inhibitor, SK&F 105657. Prostate, 21: 15-34, 1992.
36. Rittmaster, R. S., Manning, A. P., Wright, A. S. Thomas, L. N., Whitefield, S., and Norman, R. W. Evidence of atrophy and apoptosis in the ventral prostate of rats given the 5α-reductase inhibitor finasteride. Endocrinology, 136: 741-748, 1995.
37. Zaccheo, T., Giudici, D., and di Salle, E. Effects of turosteride, a 5α-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. Prostate, 30: 85-91, 1997.
38. Nakayama, O., Hirosomi, J., Chida, N., Takahashi, S., Sawada, K., Kojo, H., and Notsu, Y. FR146687, A novel steroid 5α-reductase inhibitor: in vitro and in vivo effects on prostates. Prostate, 31: 241-249, 1997.